Hormonal
Empagliflozin (10 mg/day) significantly reduces liver fibrosis (measured by liver stiffness measurement) in patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease compared to placebo, and reduces liver stiffness more effectively than pioglitazone.
If you have Type 2 Diabetes and fatty liver disease, ask your doctor about empagliflozin (10 mg daily). This study shows it can significantly reduce liver stiffness (a sign of scarring/fibrosis) better than the alternative drug pioglitazone, and better than a placebo. It also helps reduce body weight and visceral fat. Ensure you maintain moderate physical activity and follow dietary advice as part of your treatment.
Using multivariate analysis, we observed a significant reduction in the placebo-corrected change in liver stiffness measurement (LSM) with empagliflozin compared to pioglitazone: - 0.77 kPa (- 1.45, - 0.09), p = 0.02, versus 0.01 kPa (95% CI - 0.70, 0.71, p = 0.98), p for comparison = 0.03.
Why this rating
Randomized, double-blind, placebo-controlled clinical trial with a reasonable sample size (n=106), though the primary endpoint (CAP) was only borderline significant.
Source
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Haleh Chehrehgosha et al. · Diabetes Therapy · 2021
DOI 10.1007/s13300-021-01011-3
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →